HealthCare Global Enterprises Limited has successfully completed the allotment of equity shares under its rights issue and published the mandatory advertisement intimation under Regulation 92 of SEBI ICDR Regulations. The Rights Issue Committee meeting held on March 27, 2026, approved the allotment of 82,94,566 equity shares to eligible shareholders and renouncees.

Rights Issue Details

The rights issue was conducted with specific terms that provided existing shareholders the opportunity to subscribe to additional shares. The issue opened on March 11, 2026, and closed on March 25, 2026, giving eligible shareholders a two-week window to participate. The record date for determining eligible shareholders was set as March 02, 2026.

Subscription and Allotment Response

The rights issue received an overwhelming response from investors, with total applications for 10,713,388 Rights Equity Shares against the offered 82,94,566 shares. Out of 3,446 total applications, 185 applications for 12,945 shares were rejected due to technical reasons. The final valid applications totaled 3,261 for 10,700,443 Rights Equity Shares, representing 129.01% subscription of the offered shares.

Capital Structure Impact

The successful completion of the rights issue has resulted in a substantial increase in the company's paid-up equity share capital. The allotment has enhanced the company's capital base from ₹141,00,76,370 to ₹149,30,22,030, providing additional financial resources for its operations and growth initiatives.

Regulatory Compliance and Advertisement Publication

On March 30, 2026, the company published advertisements in compliance with Regulation 92 of SEBI ICDR Regulations in Financial Express (English national daily), Jansatta (Hindi national daily), and Vishwavani (Kannada daily newspaper). The advertisement detailed subscription information, basis of allotment, and credit dates for equity shares. The company has fulfilled all regulatory requirements under SEBI Master Circular and disclosed necessary information as prescribed.

Trading Commencement

The dispatch of allotment advice and unblocking intimation to investors was completed after executing corporate action for crediting equity shares into respective demat accounts on March 30, 2026. Trading in fully paid-up equity shares issued in the rights issue is expected to commence on April 1, 2026, subject to receipt of listing and trading permissions from NSE and BSE.

The rights issue represents a strategic move by HealthCare Global Enterprises to strengthen its financial position and support future business objectives. The successful completion demonstrates strong investor confidence in the company's prospects and management's ability to execute capital raising initiatives effectively.

HealthCare Global Enterprises Limited has announced a comprehensive investment plan worth ₹253.66 crore following board approvals on March 30, 2026. The healthcare company's board has sanctioned ₹98 crore for investment in HCG NCHRI LLP, its wholly owned subsidiary, and up to ₹155.66 crore for acquiring an additional 34% stake in Vizag Hospital and Cancer Research Centre Private Limited.

Board Approved Investment Breakdown

The company's board has structured the investment across two key subsidiaries to strengthen operations and expand strategic holdings.

HCG NCHRI LLP Investment Details

The ₹98 crore investment in HCG NCHRI LLP will enable pre-payment and repayment of outstanding borrowings. The subsidiary operates a 74-bedded cancer care centre in Nagpur and reported strong financial performance with revenue from operations of ₹89.80 crore and profit after tax of ₹17.02 crore for the financial year ended March 31, 2025.

Vizag Hospital Acquisition Strategy

The board's approval enables Healthcare Global Enterprises to acquire an additional 34% stake in Vizag Hospital, bringing total ownership to 85%. This acquisition follows the Share Purchase Agreement dated June 28, 2024, as amended through agreements executed on October 01, 2024 and March 29, 2026.

Financial Performance Overview

Vizag Hospital demonstrated solid operational performance with revenue from operations of ₹110.14 crore and profit after tax of ₹18.79 crore for the financial year ended March 31, 2025. The entity was incorporated on March 05, 1986, and operates from Visakhapatnam, Andhra Pradesh.

Rights Issue Alignment

Both investments align with the stated objects of the rights issue approved by the company on February 24, 2026. The rights issue allocated approximately ₹98 crore for the HCG NCHRI LLP investment and ₹154.04 crore for the Vizag Hospital acquisition, subject to adjustments or incremental payments as per agreement terms.

Strategic Implications

The board meeting, which commenced at 1:45 p.m. and concluded at 3:40 p.m. IST, reflects the company's commitment to strengthening its subsidiary network while maintaining focus on cancer care services. Both investments are expected to be completed in Q1 FY27, with no governmental or regulatory approvals required for either transaction.